Cargando…
Endocannabinoid 2-arachidonoylglycerol is elevated in the coronary circulation during acute coronary syndrome
OBJECTIVES: The endocannabinoid system modulates coronary circulatory function and atherogenesis. The two major endocannabinoids (eCB), 2-arachidonoylglycerol (2-AG) and N-arachidonoylethanolamide (AEA), are increased in venous blood from patients with coronary artery disease (CAD). However, given t...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936850/ https://www.ncbi.nlm.nih.gov/pubmed/31887202 http://dx.doi.org/10.1371/journal.pone.0227142 |
_version_ | 1783483776379125760 |
---|---|
author | Jehle, Julian Goerich, Hanna Bindila, Laura Lutz, Beat Nickenig, Georg Tiyerili, Vedat |
author_facet | Jehle, Julian Goerich, Hanna Bindila, Laura Lutz, Beat Nickenig, Georg Tiyerili, Vedat |
author_sort | Jehle, Julian |
collection | PubMed |
description | OBJECTIVES: The endocannabinoid system modulates coronary circulatory function and atherogenesis. The two major endocannabinoids (eCB), 2-arachidonoylglycerol (2-AG) and N-arachidonoylethanolamide (AEA), are increased in venous blood from patients with coronary artery disease (CAD). However, given their short half-life and their autocrine/paracrine mechanism of action, eCB levels in venous blood samples might not reflect arterial or coronary eCB concentrations. The aim of this cross-sectional study was to identify the local concentration profile of eCB and to detect whether and how this concentration profile changes in CAD and NSTEMI versus patients without CAD. METHODS AND RESULTS: 83 patients undergoing coronary angiography were included in this study. Patients were divided into three groups based on their definite diagnosis of a) no CAD, b) stable CAD, or c) non-ST-segment elevation myocardial infarction (NSTEMI). Blood was drawn from the arterial sheath and the aorta in all patients and additionally distal to the culprit coronary lesion in CAD- and NSTEMI patients. 2-AG levels varied significantly between patient groups and between the sites of blood extraction. The lowest levels were detected in patients without CAD; the highest 2-AG concentrations were detected in NSTEMI patients and in the coronary arteries. Peripheral 2-AG levels were significantly higher in NSTEMI patients (107.4 ± 28.4 pmol/ml) than in CAD- (17.4 ± 5.4 pmol/ml; p < 0.001), or no-CAD patients (23.9 ± 7.1 pmol/ml; p < 0.001). Moreover, coronary 2-AG levels were significantly higher in NSTEMI patients than in CAD patients (369.3 ± 57.2 pmol/ml vs. 240.1 ± 25.3 pmol/ml; p = 0.024). CONCLUSIONS: 2-AG showed significant variability in arterial blood samples drawn from distinct locations. Possibly, lesional macrophages synthesise 2-AG locally, which thereby contributes to endothelial dysfunction and local inflammation. |
format | Online Article Text |
id | pubmed-6936850 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-69368502020-01-07 Endocannabinoid 2-arachidonoylglycerol is elevated in the coronary circulation during acute coronary syndrome Jehle, Julian Goerich, Hanna Bindila, Laura Lutz, Beat Nickenig, Georg Tiyerili, Vedat PLoS One Research Article OBJECTIVES: The endocannabinoid system modulates coronary circulatory function and atherogenesis. The two major endocannabinoids (eCB), 2-arachidonoylglycerol (2-AG) and N-arachidonoylethanolamide (AEA), are increased in venous blood from patients with coronary artery disease (CAD). However, given their short half-life and their autocrine/paracrine mechanism of action, eCB levels in venous blood samples might not reflect arterial or coronary eCB concentrations. The aim of this cross-sectional study was to identify the local concentration profile of eCB and to detect whether and how this concentration profile changes in CAD and NSTEMI versus patients without CAD. METHODS AND RESULTS: 83 patients undergoing coronary angiography were included in this study. Patients were divided into three groups based on their definite diagnosis of a) no CAD, b) stable CAD, or c) non-ST-segment elevation myocardial infarction (NSTEMI). Blood was drawn from the arterial sheath and the aorta in all patients and additionally distal to the culprit coronary lesion in CAD- and NSTEMI patients. 2-AG levels varied significantly between patient groups and between the sites of blood extraction. The lowest levels were detected in patients without CAD; the highest 2-AG concentrations were detected in NSTEMI patients and in the coronary arteries. Peripheral 2-AG levels were significantly higher in NSTEMI patients (107.4 ± 28.4 pmol/ml) than in CAD- (17.4 ± 5.4 pmol/ml; p < 0.001), or no-CAD patients (23.9 ± 7.1 pmol/ml; p < 0.001). Moreover, coronary 2-AG levels were significantly higher in NSTEMI patients than in CAD patients (369.3 ± 57.2 pmol/ml vs. 240.1 ± 25.3 pmol/ml; p = 0.024). CONCLUSIONS: 2-AG showed significant variability in arterial blood samples drawn from distinct locations. Possibly, lesional macrophages synthesise 2-AG locally, which thereby contributes to endothelial dysfunction and local inflammation. Public Library of Science 2019-12-30 /pmc/articles/PMC6936850/ /pubmed/31887202 http://dx.doi.org/10.1371/journal.pone.0227142 Text en © 2019 Jehle et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Jehle, Julian Goerich, Hanna Bindila, Laura Lutz, Beat Nickenig, Georg Tiyerili, Vedat Endocannabinoid 2-arachidonoylglycerol is elevated in the coronary circulation during acute coronary syndrome |
title | Endocannabinoid 2-arachidonoylglycerol is elevated in the coronary circulation during acute coronary syndrome |
title_full | Endocannabinoid 2-arachidonoylglycerol is elevated in the coronary circulation during acute coronary syndrome |
title_fullStr | Endocannabinoid 2-arachidonoylglycerol is elevated in the coronary circulation during acute coronary syndrome |
title_full_unstemmed | Endocannabinoid 2-arachidonoylglycerol is elevated in the coronary circulation during acute coronary syndrome |
title_short | Endocannabinoid 2-arachidonoylglycerol is elevated in the coronary circulation during acute coronary syndrome |
title_sort | endocannabinoid 2-arachidonoylglycerol is elevated in the coronary circulation during acute coronary syndrome |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936850/ https://www.ncbi.nlm.nih.gov/pubmed/31887202 http://dx.doi.org/10.1371/journal.pone.0227142 |
work_keys_str_mv | AT jehlejulian endocannabinoid2arachidonoylglyceroliselevatedinthecoronarycirculationduringacutecoronarysyndrome AT goerichhanna endocannabinoid2arachidonoylglyceroliselevatedinthecoronarycirculationduringacutecoronarysyndrome AT bindilalaura endocannabinoid2arachidonoylglyceroliselevatedinthecoronarycirculationduringacutecoronarysyndrome AT lutzbeat endocannabinoid2arachidonoylglyceroliselevatedinthecoronarycirculationduringacutecoronarysyndrome AT nickeniggeorg endocannabinoid2arachidonoylglyceroliselevatedinthecoronarycirculationduringacutecoronarysyndrome AT tiyerilivedat endocannabinoid2arachidonoylglyceroliselevatedinthecoronarycirculationduringacutecoronarysyndrome |